Technology Subtype

Small Molecule

114 results

(0.12 seconds)

PROTAC treatment for HIV

06285

PROTACs selectively degrade HIV Nef, restoring immune recognition and suppressing HIV replication, aiming for reservoir clearance.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Lead Inventor: Thomas Smithgall
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Lori Ann Emert-Sedlak
Allen B. Reitz
Thomas E. Smithgall
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-02-06

Innovative Small Molecule for Zika Virus Neutralization

06214

CZV1-1: first nonpeptide Zika neutralization surrogate enabling highly specific, room-temperature diagnostics and research tools.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Zika
Lead Inventor: Donald Burke
Department: GSPH-Epidemiology
All Tech Innovators: Donald S. Burke
Priscila Mayrelle Da Silva Castanha
Ernesto Torres De Azeved Marques Jr
Date Submitted: 2022-11-14
Collections: Women's & Reproductive Health

Small Molecule Allosteric Modulators of Class B GPCRs in the PTHR and Method to Identify Them

05559

Structure-guided discovery yields four small-molecule negative allosteric modulators of PTHR, offering oral, targeted osteoporosis therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Endocrinology and Metabolic Diseases
Lead Inventor: Ieva Sutkeviciute
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Ivet Bahar
Pemra Doruker
Jiyoung Lee
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-11-19
Collections: Cardiometabolic
Women's & Reproductive Health

Novel Compounds to Inhibit TNF-Induced NF-κB Pathways

04864

Network-centric discovery yields two first-in-class small molecules selectively blocking TNF-induced NF-κB signaling, reducing off-target effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Tags: Autoimmune
Lead Inventor: Carlos Camacho
Department: Med-Computational and Systems Biology
All Tech Innovators: Carlos Jaime Camacho
Robin E C Lee
Date Submitted: 2019-01-22

Small Molecule Drug for Targeting Resistant Prostate Cancer

07323

New class of nuclear AR-degrading small molecules (NARDs) selectively targets resistant prostate cancer by degrading AR in the nucleus.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Timothy James Casad
Joel B. Nelson
Zhou Wang
Date Submitted: 2025-09-02

Novel Therapy for Chondrocyte Aging and Osteoarthritis

07004

GATA4-targeting small molecule HCA42027 may restore aged chondrocyte repair, offering a potential disease-modifying OA therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Musculoskeletal
Therapeutic Indications: Heart failure
Atherosclerotic disease
Osteoarthritis
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Hang Lin
Department: Med-Orthopedic Surgery
All Tech Innovators: Olivia Grace Bartholomew
Kate Li
Hang Lin
Date Submitted: 2024-12-11
Collections: Cardiometabolic

Targeted HDAC 8 Inhibitors for Managing Kidney Disease

06617

Indole-based HDAC-8 inhibitors offer targeted, potentially less toxic kidney disease therapy; prototype-stage, organoid-supported efficacy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Nephrology
Therapeutic Indications: Acute Kidney Injury (AKI)
Lead Inventor: Donna Huryn
All Tech Innovators: Neil A. Hukriede
Donna Huryn
Sangeetha Subramani
Date Submitted: 2024-01-26

Novel Glutamate Receptor Agonists

06272

Glutamate receptor agonist SYM2081 dampens dermal mast cell activation, offering potential treatments for dermatitis, rosacea, and hypersensitivity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Dermatology
Therapeutic Indications: Dermatitis
Lead Inventor: Daniel Kaplan
Department: Med-Dermatology
All Tech Innovators: Daniel H. Kaplan
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-01-24

NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties

05522

Novel Nampt inhibitors deliver strong potency and favorable ADME, enabling chemotherapy and immune support benefits.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Oncology
Tags: Autoimmune
Immuno-oncology
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-06

Mitoparib: A Mitochondrial PARP Inhibitor that Counteracts Metabolic Stress

03916

Mitochondria-targeted PARP inhibitor that preserves mitochondrial NAD+, preventing stress-induced necrosis without hindering nuclear DNA repair.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Hulya Bayir
Robert B. Clark
Tanja Krainz
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-04-23

Borylated Esters and Acetals as Cancer Prodrugs

06731

Boronate-protected prodrugs release cytotoxins in peroxide-rich cancer cells, enabling targeted, reduced-side-effect chemotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Lead Inventor: Paul Floreancig
Department: Chemistry
All Tech Innovators: Alexander Deiters
Paul Edward Floreancig
Paul Joseph Geaneotes
Date Submitted: 2024-04-29

HIF1 Activators as Therapeutics for Triosephosphate Isomerase Deficiency (TPI Df)

07001

HIF1-activating triazines boost TPI expression, repurposing approved PHD inhibitors (e.g., vadadustat) for TPI deficiency.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Lead Inventor: Michael Palladino
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Michael John Palladino
Andreas Vogt
Date Submitted: 2024-12-09

Nitro-fatty Acids for Treating Aortic Aneurysm

05302

Nitro-oleic acid (nitro-fatty acid) shows promise halting abdominal aortic aneurysm progression via anti-inflammatory effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Therapeutic Indications: Other
Lead Inventor: Francisco Schopfer
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Yuqing Eugene Chen
Bruce A. Freeman
Francisco Jose Schopfer PhD
Date Submitted: 2020-04-13
Collections: Cardiometabolic

Novel Selective Kv7 Channel Modulators

06017

Selective novel chemotypes selectively modulate Kv7.2 channels, enabling safer treatments for epilepsy, tinnitus, channelopathies.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Cardiovascular
Tags: Life Science
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Peter Wipf
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-05-02
Collections: Cardiometabolic

Next Generation Targeted Nitroxides

05064

New nitroxide-based lipids curb mitochondrial lipid peroxidation to block ferroptosis, aiding ischemia, AKI, and neurodegenerative therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Nephrology
Therapeutic Indications: Acute Kidney Injury (AKI)
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Peter Wipf
Date Submitted: 2019-07-20
Collections: Cardiometabolic

Universal Vaccine for SARS-CoV-2 (COVID 19)

05356

Universal vaccine approach targets SARS-CoV-2 RdRp activation motif, potentially halting replication across coronaviruses.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Covid-19
Lead Inventor: Patrick Moore
Department: Med-Pathology
All Tech Innovators: Yuan Chang
Patrick S. Moore
Masahiro Shuda
Date Submitted: 2020-05-13

Dipeptidyl Peptidase-4 (DPP4) Inhibitors for Inhibiting Posterior Capsular Opacification

07055

DPP4 inhibitors prevent posterior capsular opacification after cataract surgery via EMT suppression, offering non-invasive, targeted ocular protection.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Ophthalmology
Therapeutic Indications: Cataracts
Tags: Aging
Drug Repurposing
Lead Inventor: Kun Che Chang
Department: Med-Ophthalmology
All Tech Innovators: Kun Che Chang
Chi-Yu Chen
Pei-Kang Liu
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-01-31
Collections: Regenerative Medicine

Novel Treatment for Retinitis Pigmentosa

06383

Pyrvinium targets NS LLPS to restore proteostasis, preserve retinal structure, and may treat retinitis pigmentosa and proteinopathies.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Ophthalmology
Therapeutic Indications: Parkinson's Disease
Alzheimer's Disease
Retinitis pigmentosa (RP)
Tags: Life Science
Lead Inventor: Bokai Zhu
Department: Med-Medicine
All Tech Innovators: Yuanyuan Chen
William A. Dion
Bokai Zhu
Date Submitted: 2023-04-23

Novel Approach to Bone Regeneration

06099

Activates skeletal stem cells to regenerate bone endogenously, using mechanical suture expansion and niclosamide-based stimulation.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Dental
Musculoskeletal
Therapeutic Indications: Osteoporosis
Tags: Regenerative medicine
Lead Inventor: Giuseppe Intini
Department: Dent Med-Periodontics/Preventive Dentistry
All Tech Innovators: Xue Hui Geng
Giuseppe Intini
Luigi Mancinelli
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2022-07-13
Collections: Women's & Reproductive Health

Antioxidant Therapy for Treating Propionic and Methylmalonic Acidemia

05544

Mitochondria-targeted antioxidants offer a non-invasive therapy to lower reactive oxygen, mitigating damage in propionic and methylmalonic acidemia.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Therapeutic Indications: Other
Mitochondrial Disease
Tags: Pediatrics
Rare disease
Lead Inventor: Gerard Vockley
Department: Med-Pediatrics
All Tech Innovators: Gerard Vockley
Peter Wipf
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-30
Collections: Cardiometabolic

RNF167 and CASTOR1 as Novel mTOR Targets

05450

Novel RNF167-CASTOR1 axis activates mTORC1, promoting cancer; potential drug targets and prognostic biomarkers.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Shou-Jiang Gao
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Shou-Jiang Gao
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-07-16
Collections: Women's & Reproductive Health

Novel Small Molecules for Inhibition of MALT1

05186

Innovative MALT1 inhibitors block both protease and scaffolding functions, expanding cancer and autoimmune therapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Oncology
Tags: Autoimmune
Immuno-oncology
Lead Inventor: Peter Lucas
All Tech Innovators: Beibei Chen
Dong Hu
Heejae Kang
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-30
Collections: Women's & Reproductive Health

Novel Glycine Receptor Modulators for Analgesia

04250

Glycine receptor modulators (ZINC08) enhance analgesia without THC's psychoactivity, enabling opioid-sparing pain relief.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Lead Inventor: Yan Xu
Department: Med-Anesthesiology and Perioperative Medicine
All Tech Innovators: Pei Tang
Marta Megan Wells
Yan Xu
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2017-05-17

Novel Class Therapeutic Psychedelics

05753

Novel clavine psychedelics: total synthesis enables SAR-driven development of non-hallucinogenic, CNS-targeting therapeutic candidates.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Mental and Behavioral Health
Therapeutic Indications: Depression
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Ethan James Pazur
Nikhil Rushi Tasker
Peter Wipf
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-07-02

Anaplerotic TCA Cycle Prodrugs for Restoring Mitochondrial Metabolism for Organic Acidemia and Fatty Acid Oxidation Disorders

03786

Multi-moiety glycerol prodrugs deliver diverse TCA substrates to restore mitochondrial metabolism in organic acidemias and fatty acid disorders.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Therapeutic Indications: Other
Tags: Genetics
Pediatric Medicine
Lead Inventor: Gerard Vockley
Department: Med-Pediatrics
All Tech Innovators: Al-Walid A. Mohsen
Gerard Vockley
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2015-12-14
Collections: Cardiometabolic

Novel Activators of AMP-activated Protein Kinase

03887

New nanomolar small molecules block AMPK ubiquitination, stabilizing and activating AMPK to treat metabolic, inflammatory, and cancer disorders.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Endocrinology and Metabolic Diseases
Tags: Aging
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Yuan Liu
Rama K. Mallampalli
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-04-05
Collections: Cardiometabolic

Novel Carbamates as Treatment for Tinnitus

03415

Potent, selective carbamates target KCNQ2/3 channels to reduce tinnitus and potentially treat epilepsy, via auditory synapse modulation.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Otolaryngology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Athanassios Tzounopoulos
Peter Wipf
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2014-10-03

Novel Mitochondrial Targeting Nitroxides for Radioprotection and the Treatment of Associated Pathologies

02662

Mitochondria-targeted nitroxide JP4-039 shields tissue from ROS and radiation, aiding healing with topical/oral delivery.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Peter Wipf
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2012-04-11
Collections: Regenerative Medicine
Cardiometabolic

Novel Senotherapeutic Agents for Cancer Therapy

06267

Senotherapeutic sGC activator cinaciguat induces apoptosis in senescent prostate cancer cells, reducing recurrence and BPH progression.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Urology
Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Aging
Lead Inventor: Anthony Kanai
Department: Med-Medicine
All Tech Innovators: Youko Ikeda
Anthony J. Kanai
Irina Valerjevna Zabbarova
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-01-12

Pfn1 as a Novel Therapeutic Target for Atherosclerosis

06880

Pfn1 inhibitors block actin interaction, offering a novel anti-atherosclerosis approach with anti-angiogenic potential.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Therapeutic Indications: Atherosclerotic disease
Lead Inventor: David Gau
Department: Med-Pathology
All Tech Innovators: David Martin Gau
Abigail Gondringer
Donna Huryn
Date Submitted: 2024-09-17
Collections: Cardiometabolic

Novel Approach for Cartilage Repair

05596

Wnt inhibitors with microfracture improve cartilage repair by promoting hyaline cartilage and reducing fibrosis, via targeted intra-articular delivery.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Therapeutic Indications: Other
Lead Inventor: Hang Lin
Department: Med-Orthopedic Surgery
All Tech Innovators: Hang Lin
Date Submitted: 2021-01-18
Collections: Regenerative Medicine

Small-Molecule Stabilizers of TFEB for Local Ocular Delivery in Age-Related Retinal Disease

04690

Small-molecule TFEB activator GT300 enables intravitreal, sustained TFEB activation to boost retinal autophagy/lysosome function.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Ophthalmology
Therapeutic Indications: Glaucoma
Geographic atrophy
Age-related macular degeneration
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2018-07-26

NKCC Inhibitors for Neuroprotection Following a Stroke

04461

Novel brain-targeted NKCC1 inhibitors (e.g., STS66) outperform bumetanide, reducing stroke damage while limiting diuretic side effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Lead Inventor: Dandan Sun
Department: Med-Neurology
All Tech Innovators: Thomas Erker
Philipp Schreppel
Dandan Sun
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2018-01-10

Targeting Genetic Changes in IDH-Mutant Gliomas with a Novel Use of an FDA-Approved Drug

04124

FDA-approved drug repurposed to target IDH-mutant gliomas, boosting immune attack and shrinking tumors in mice and humans.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Ndukaku Amankulor
Department: Med-Neurological Surgery
All Tech Innovators: Ndukaku Mgbechinyere Amankulor
Aparna Vijaykumar Rao
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2017-01-10

Novel Nitro Nitrate Lipid Intermediates that Mediate Nitrosating and Alkylating Reactions

03996

Nitro-nitrate-lipid intermediates act as versatile NO donors, offering vasodilation with dual nitrosating/alkylating actions for CVD therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Lead Inventor: Marco Fazzari
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Marco Fazzari
Bruce A. Freeman
Francisco Jose Schopfer PhD
Date Submitted: 2016-07-19
Collections: Cardiometabolic

p97 ATPase Inhibitors for Cancer and Neurodegneration

03811

Allosteric p97 inhibitors selectively impair cancer and neurodegenerative pathways by blocking p97 ATPase function.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Lead Inventor: Donna Huryn
All Tech Innovators: Donna Huryn
Matthew G. LaPorte
Peter Wipf
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-01-26

Novel Therapy to Prevent Organ Transplant Rejection

06909

WS6 inhibitor targets tissue-resident memory T cells, potentially preventing organ transplant rejection with reduced broad immunosuppression.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Therapeutic Indications: Other
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Khodor Abou Daya
Department: Med-Surgery
All Tech Innovators: Khodor Abou Daya
Date Submitted: 2024-10-01

A Novel Treatment for Metastatic Prostate Cancer

06044

Novel allosteric AR modulators found to disrupt AR-TIF2 signaling, offering potential treatment for metastatic castration-resistant prostate cancer.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Paul Johnston
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Carlos Jaime Camacho
Andrew P. Hinck
Paul A. Johnston
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-06-01

New Methodology Increases NAMPT Activity for Treating Several Diseases including Autoimmune Conditions

05563

New NAMPT-activating compounds boost NAD+ to treat obesity, autoimmune disorders, aging, kidney injury, and cognitive decline.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Endocrinology and Metabolic Diseases
Therapeutic Indications: Obesity
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-11-23
Collections: Cardiometabolic

Next-Generation Small Molecule Therapeutics Targeting the GSTP1-ISCU Axis for Pulmonary Hypertension Treatment

05445

Targeting GSTP1-ISCU axis with piperlongumine analogs to treat pulmonary hypertension, improving endothelial function and reducing mitochondrial stress.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Therapeutic Indications: Pulmonary arterial hypertension (PAH)
Tags: Rare disease
Lead Inventor: Stephen Chan
Department: Med-Medicine
All Tech Innovators: Stephen Yu-Wah Chan MD, PhD
Seungchan Kim PhD
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-07-14
Collections: Cardiometabolic

Glutaminase Inhibitors

03304

Novel glutaminase inhibitors starve cancer cells of glutamine, showing in vivo tumor suppression and potential TNBC therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Lead Inventor: Lee McDermott
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Prema Chandrasekhar Iyer
Lee Apostle McDermott
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2014-04-29
Collections: Women's & Reproductive Health

A Simple, Effective, and Dual-Functional Drug Delivery Platform for Hydrophobic Agents

03178

Dual-functional PEG-FTS micellar system enhances solubility, targets tumors, and co-delivers hydrophobic anticancer drugs with reduced toxicity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Song Li
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Xiang Gao
Yixian Huang
Song Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2013-11-22

Small Molecule Antagonists of HIV Nef Function

02843

Small molecule inhibitors block HIV Nef function, offering potential combination therapies to reduce resistance and toxicity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Therapeutic Indications: HIV
Lead Inventor: Thomas Smithgall
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Billy W. Day
Lori Ann Emert-Sedlak
Prema Chandrasekhar Iyer
Date Submitted: 2012-07-25
Collections: Women's & Reproductive Health

Small Molecule Inhibitor Therapy to Prevent Aneurysm Formation, Growth, and Rupture

05390

Small molecule inhibitors block CXCL7-CXCR1/2 inflammation to prevent cerebral aneurysm formation, growth, and rupture.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Neuroscience
Lead Inventor: Robert Friedlander
Department: Med-Neurological Surgery
All Tech Innovators: Michael P. D'Angelo
Robert Max Friedlander
Wendy Fellows Mayle
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2020-05-30
Collections: Regenerative Medicine
Cardiometabolic

Novel Thiadiazines as Heat Shock Protein Modulators and Anti-Huntington Disease Therapeutic Agents

05177

Novel thiadiazine modulators target Hsp70, offering potential Huntington and neurodegenerative disease therapies via protein homeostasis regulation.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Jeffrey L. Brodsky Ph.D.
Linh Khai Ngo
Leila Terrab
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-20

Anti-Inflammatory Small Molecules for Treatment of Chronic Inflammatory Disorders

04731

New class of small-molecule NF-κB inhibitors reduces chronic inflammation; potential for asthma, arthritis, IBD, cancer, aging benefits.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Gastroenterology
Respiratory
Therapeutic Indications: Ulcerative Colitis
Asthma
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2018-09-10

Novel Small Molecule Therapeutics for Hemorrhagic Shock

01198

Mitochondria-targeted antioxidant therapy for hemorrhagic shock using XJB-5-131 delivers TEMPO directly, extending survival.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Endocrinology and Metabolic Diseases
Cardiovascular
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Mitchell Phillip Fink MD
Valerian E. Kagan PhD, DSc
Yulia Yurjevna Tyurina
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2006-01-03
Collections: Cardiometabolic
Women's & Reproductive Health

Enzyme Inhibitor Promotes Anticancer Immune Response

05716

Novel ALDH1A inhibitor boosts dendritic and T cell responses, enhances vaccine-driven tumor control in hard-to-treat cancers.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Oncology
Tags: Immuno-oncology
Lead Inventor: Ronald Buckanovich
Department: Med-Medicine
All Tech Innovators: Ronald J. Buckanovich
Anda Mioara Vlad
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-06-08
Collections: Women's & Reproductive Health

300 Novel CB1 Antagonists Hold Potential for new Treatments

05523

New, structurally distinct CB1 antagonists offer broad potential for metabolic therapies and weight management. 15 words max, 120-150 characters.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Neuroscience
Endocrinology and Metabolic Diseases
Therapeutic Indications: Obesity
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-10-06
Collections: Cardiometabolic

Therapeutic Targets for TPI Deficiency

05520

Identifies novel regulators of mutant TPI turnover, revealing drug targets to stabilize cytosolic proteins for TPI deficiency.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Hematology
Tags: Rare disease
Lead Inventor: Michael Palladino
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Stacy Lynn Hrizo
Michael John Palladino
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-05